# DESTINY-Breast06 (NCT04494425)

> Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

No report yet. It can be ordered.

- Drugs tested: trastuzumab deruxtecan
- Indication: hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04494425
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced or Metastatic Breast Cancer
- Interventions: Trastuzumab deruxtecan; Capecitabine; Paclitaxel; Nab-Paclitaxel
- Enrollment: 866
- Primary outcome: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population

## Questions raised in the commentary

_Automated from the 40 newest of 517 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- How to sequence trastuzumab deruxtecan with other antibody–drug conjugates
- Whether to use chemotherapy or an antibody–drug conjugate after endocrine therapy
- How trastuzumab deruxtecan compares with newer antibody–drug conjugates

Also discussed: antibody–drug conjugate toxicity profiles, HER2 testing and expression heterogeneity.

## Indexed commentary on DESTINY-Breast06 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 196
- YouTube: 170
- Podcasts: 131
- Bluesky threads: 16
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-breast06-nct04494425

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04494425", "email": "<work email>"}; the inbox owner confirms by the emailed link.